Ibithral 200 Rediuse Oral Suspension contains Azithromycin at a concentration of 200 mg per 5 ml, a macrolide antibiotic effective against a broad spectrum of bacterial infections. It is indicated for the treatment of respiratory tract infections, skin and soft tissue infections, otitis media, pharyngitis, tonsillitis, and certain sexually transmitted infections caused by susceptible strains of bacteria. Azithromycin exerts its antibacterial activity by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, thereby preventing bacterial growth. The oral suspension formulation allows for ease of administration, particularly in pediatric and geriatric populations or patients with swallowing difficulties. The dosage and duration of therapy should be determined based on the type and severity of infection, as well as patient-specific factors such as age and renal function. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. Hypersensitivity reactions, although rare, may occur. Ibithral 200 Rediuse Oral Suspension should be used with caution in patients with hepatic impairment and cardiac conduction abnormalities due to the potential risk of QT prolongation. It is contraindicated in patients with known hypersensitivity to azithromycin or other macrolides. Proper adherence to prescribed dosing is essential to minimize resistance development and ensure therapeutic efficacy.